Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia

被引:0
作者
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Weiss, Jocelyn [1 ]
Bradstock, Ken
Bendall, Linda J.
机构
[1] Westmead Hosp, Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1336 / 1336
页数:1
相关论文
共 50 条
[31]   PI3K/Akt/mTOR inhibitors in breast cancer [J].
Joycelyn JX Lee ;
Kiley Loh ;
Yoon-Sim Yap .
Cancer Biology & Medicine, 2015, 12 (04) :342-354
[32]   REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFIELDS) THROUGH ACTIVATION OF THE PI3K/AKT/MTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/MTOR DUAL INHIBITORS [J].
Klein-Goldberg, Anat ;
Voloshin, Tali ;
Zemer-Tov, Efrat ;
Paz, Rom ;
Koren, Lilach ;
Wainer-Katsir, Kerem ;
Volodin, Alexandra ;
Koltun, Bella ;
Brant, Boris ;
Haber, Adi ;
Giladi, Moshe ;
Weinberg, Uri ;
Palti, Yoram .
NEURO-ONCOLOGY, 2021, 23 :84-84
[33]   How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia? [J].
Pinchinat, Ashley ;
Raetz, Elizabeth .
HAEMATOLOGICA, 2022, 107 (10) :2292-2294
[34]   PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress [J].
Wu, P. ;
Hu, Y-Z .
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) :4326-4341
[35]   Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells [J].
Ina Nepstad ;
Kimberley Joanne Hatfield ;
Ida Sofie Grønningsæter ;
Elise Aasebø ;
Maria Hernandez-Valladares ;
Karen Marie Hagen ;
Kristin Paulsen Rye ;
Frode S. Berven ;
Frode Selheim ;
Håkon Reikvam ;
Øystein Bruserud .
Signal Transduction and Targeted Therapy, 4
[36]   4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors [J].
Liu, Kevin K-C. ;
Bagrodia, Shubha ;
Bailey, Simon ;
Cheng, Hengmiao ;
Chen, Hui ;
Gao, Lisa ;
Greasley, Samantha ;
Hoffman, Jacqui E. ;
Hu, Qiyue ;
Johnson, Ted O. ;
Knighton, Dan ;
Liu, Zhengyu ;
Marx, Matthew A. ;
Nambu, Mitchell D. ;
Ninkovic, Sacha ;
Pascual, Bernadette ;
Rafidi, Kristina ;
Rodgers, Caroline M-L. ;
Smith, Graham L. ;
Sun, Shaoxian ;
Wang, Haitao ;
Yang, Anle ;
Yuan, Jing ;
Zou, Aihua .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (20) :6096-6099
[37]   Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells [J].
Nepstad, Ina ;
Hatfield, Kimberley Joanne ;
Gronningsaeter, Ida Sofie ;
Aasebo, Elise ;
Hernandez-Valladares, Maria ;
Hagen, Karen Marie ;
Rye, Kristin Paulsen ;
Berven, Frode S. ;
Selheim, Frode ;
Reikvam, Hakon ;
Bruserud, Oystein .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
[38]   Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines [J].
Yuan, Jing ;
Garza, Scott J. ;
Cao, Joan ;
Fisher, Timothy S. ;
Lee, Nathan V. ;
Eisele, Koleen ;
Pasis, Angela ;
Hook, Kenneth ;
Christensen, James G. ;
Kan, Julie L. .
CANCER RESEARCH, 2012, 72
[39]   Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track? [J].
Mangala, Shenoy K. ;
Rathi, Ekta ;
Udupa, Karthik S. ;
Shama, Prasada K. ;
Pai, K. Sreedhara Ranganath ;
Kini, Suvarna G. .
CURRENT MEDICINAL CHEMISTRY, 2025, 32 (06) :1121-1143
[40]   Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response? [J].
Ekshyyan, Oleksandr ;
Anandharaj, Arunkumar ;
Nathan, Cherie-Ann O. .
CLINICAL CANCER RESEARCH, 2013, 19 (14) :3719-3721